Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resolving a Complex Neonatal Phenotype by Rapid Trio Whole-Genome Sequencing: A De Novo 11q14.3-q22.3 Deletion and a Splicing-Altering Synonymous ANK1 Variant.

Journal of clinical laboratory analysis·2026
Same author

Clinical vulnerability to chemotherapy in cholangiocarcinoma: impact of nutritional status, frailty, and systemic inflammation.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Feasibility and performance evaluation of a robotic steerable endoscopic submucosal dissection knife (with video).

Scientific reports·2026
Same author

Korean clinical practice guidelines for bowel preparation before colonoscopy.

Clinical endoscopy·2026
Same author

Frailty, nutritional status, and inflammation as determinants of chemotherapy delivery and outcomes in pancreatic cancer patients receiving gemcitabine plus nab-paclitaxel.

Frontiers in oncology·2026
Same author

JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Jun 20, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Hypersensitivity reactions to oxaliplatin.

Kyoung-Hwan Lee1, Yong Jai Park, Eun Sun Kim

  • 1Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.

Cancer Research and Treatment
|September 23, 2009
PubMed
Summary

Hypersensitivity reactions to oxaliplatin, a chemotherapy drug for colorectal cancer, are rare but increasingly reported. This study highlights two cases of severe reactions, emphasizing the need for physician vigilance during treatment.

Keywords:
ChemotherapyHypersensitivityOxaliplatin

Related Experiment Videos

Last Updated: Jun 20, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Oxaliplatin is a vital platinum-based chemotherapy agent used for colorectal and gastric cancers.
  • While generally safe, oxaliplatin can rarely cause hypersensitivity and idiosyncratic reactions.
  • Increasing clinical use necessitates awareness of potential adverse events.

Purpose of the Study:

  • To report two cases of hypersensitivity reactions in patients receiving oxaliplatin-based chemotherapy.
  • To underscore the importance of recognizing and managing oxaliplatin-induced hypersensitivity.
  • To alert clinicians to the potential for increasing incidence of these reactions.

Main Methods:

  • Case report detailing two patients with metastatic colorectal cancer undergoing palliative chemotherapy.
  • Observation of adverse events during oxaliplatin infusion cycles.
  • Clinical assessment of hypersensitivity reactions, including anaphylaxis and febrile episodes.

Main Results:

  • Patient 1 experienced an immediate anaphylactic reaction during the 7th-8th cycle of oxaliplatin.
  • Patient 2 developed recurrent febrile episodes between the 4th-8th cycles of oxaliplatin.
  • Both cases demonstrate significant hypersensitivity responses to oxaliplatin treatment.

Conclusions:

  • Hypersensitivity reactions to oxaliplatin, though uncommon, are being observed with greater frequency.
  • Vigilant monitoring for clinical signs of hypersensitivity is crucial for patient safety.
  • Early recognition and management are essential for patients receiving oxaliplatin chemotherapy.